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Lysine acetylation regulates gene expression
through modulating protein-protein interactions in
chromatin. Chemical inhibition of acetyl-lysine bind-
ing bromodomains of the major chromatin regulators
BET (bromodomain and extraterminal domain) pro-
teins has been shown to effectively block cell prolif-
eration in cancer and inflammation. However,
whether selective inhibition of individual BET bromo-
domains has distinctive functional consequences
remains only partially understood. In this study, we
show that selective chemical inhibition of the first
bromodomain of BET proteins using our small-mole-
cule inhibitor, Olinone, accelerated the progression
of mouse primary oligodendrocyte progenitors
toward differentiation, whereas inhibition of both
bromodomains of BET proteins hindered differentia-
tion. This effect was target specific, as it was not
detected in cells treated with inactive analogs and
independent of any effect on proliferation. Therefore,
selective chemical modulation of individual bromo-
domains, rather than use of broad-based inhibitors,
may enhance regenerative strategies in disorders
characterized by myelin loss such as aging and neu-
rodegeneration.
INTRODUCTION
Lysine acetylation plays an essential role in gene transcriptional
regulation. The evolutionarily conserved bromodomain (BrD)
functions as the acetyl-lysine binding domain (Dhalluin et al.,
1999) for acetylated histones and transcription factors, which
is required for ordered gene transcription in chromatin (Sanchez
and Zhou, 2009). BRD4 is a representative member of the BET
(bromodomain and extraterminal domain) family of proteins,
characterized by two tandem BrDs (BrD1 and BrD2) followed
by an extraterminal domain. Through its BrD/acetyl-lysine bind-
ing, BRD4 functions to facilitate recruitment of transcription fac-Chemistry & Biology 21,tors to target genes, assembly of the mediator complex at
enhancer sites, and activation of paused RNA polymerase II
complexes for productive transcriptional elongation (Chiang,
2009). Numerous studies have reported that broad chemical
inhibition of both BET BrDs effectively blocked genome-wide
transcription. This was particularly true for genes regulating
proliferation of cancer cells, including NUT midline carcinoma
(Filippakopoulos et al., 2010), acute myeloid leukemia (Zuber
et al., 2011), MLL-fusion leukemia (Dawson et al., 2011), and
neuroblastoma (Puissant et al., 2013). It was also suggested
that by modulating gene transcription in immune cells, BrD
inhibition has a therapeutic role in inflammatory diseases (Nico-
deme et al., 2010; Zhang et al., 2012a). However, the use of
selective inhibitors of single BrDs could have distinctive func-
tional features.
We addressed this question in oligodendrocyte lineage cells,
themyelin-forming cells of the central nervous systemwhose dif-
ferentiation has been previously shown to require cell-cycle exit
(Casaccia-Bonnefil and Liu, 2003; He et al., 2007; Magri et al.,
2014a, 2014b) and histone deacetylase activity (Marin-Husstege
et al., 2002; He et al., 2007; Shen et al., 2008). In this lineage, the
early progenitor stage is characterized by global protein lysine
acetylation and decreased global histone acetylation, previously
identified as critical for the proper onset of oligodendrocyte dif-
ferentiation (Shen et al., 2008; Wu et al., 2012; Ye et al., 2009).
Therefore, we reasoned that oligodendrocyte lineage cells would
be a suitable biological system to test the functional conse-
quences of BET protein BrD inhibition using chemical inhibitors
selective for only one or both BrDs of BET proteins.
Notably, previous studies have reported distinctive functions
of the two BrDs of BET proteins, possibly consequent to the
interaction with lysine-acetylated histones or with transcriptional
proteins (Gamsjaeger et al., 2011; Huang et al., 2009; Jang et al.,
2005; Lamonica et al., 2011; Schro¨der et al., 2012; Shi et al.,
2014; Yang et al., 2005; Zhang et al., 2012a). In the case of hu-
man BRD4, the first BrD appears dedicated to anchoring this
molecule and its associated proteins to target gene promoter
and enhancer sites in chromatin, through binding to diacetylated
H4K5ac/K8ac (a mark for gene transcriptional activation), while
the second BrD was associated with the recruitment of nonhis-
tone proteins (i.e., transcription factors and the pTEFb complex)
to target genes. In the case of BRD3, however, it is the first BrD841–854, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 841
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(Gamsjaeger et al., 2011; Lamonica et al., 2011), thereby sug-
gesting context-dependent different functions of the two BrDs
of the BET proteins in the regulation of ordered gene transcrip-
tion in chromatin.
This distinctive and unique ligand-binding selectivity of the two
BrDs has been attributed to a few amino acid residues that
distinguish the first and second BrDs within each BET protein,
while they all share nearly identical residues at the corresponding
acetyl-lysine binding pocket. In an effort to understand specific
molecular functions of the individual BrDs of BET proteins, we
developed small-molecule chemical inhibitors that are capable
of selectively modulating acetyl-lysine binding activity of the first
and/or second BrDs of BET proteins and evaluated their effects
on the progression of oligodendrocyte progenitor cells (OPCs)
toward differentiation.
RESULTS AND DISCUSSION
Structure-Guided Development of the Selective BET
BrD Inhibitor Olinone
We used a structure-guided design strategy to develop selective
small-molecule inhibitors for the BET BrDs (Figure 1A). Our
rational design of BET-specific BrD inhibitors (BrDis) started
with a chemical scaffold of tetrahydro-pyrido indole that was
present in a nuclear magnetic resonance (NMR)-based screen
hit (MS7972) and showed modest activity as an inhibitor of the
CBP BrD (Figure 1B) (Sachchidanand et al., 2006). This chemical
scaffold is amendable to varying chemical modifications that can
be synthetically added on to optimize its interactions with a
target protein. Guided by the structural insights of MS7972
bound to the CBP BrD, we designed a series of 1-substituted-
2,3,4,5-tetrahydro-pyrido-[4,3-b]indol-1-ones as inhibitors for
the BET BrDs. These molecules extend from the key features
present on MS7972 for the binding to the BET BrDs to contain
a longer acetamidoalkyl substituent at the N-indole as well as
an endocyclic peptide bond to enhance interactions with the
BrDs (Figure 1B).
The synthesis of these compounds was achieved in four steps
(see Figure S1 available online). Phenylhydrazone 1 was pre-
pared by reaction of phenylhydrazine with 2,4-piperidinedione
in water (with 10% acetic acid) under nitrogen atmosphere.
Next, the pyrido-indole scaffold was constructed by FisherFigure 1. Structure-Guided Design of Olinone, a Selective Inhibitor for
(A) Schematic illustration of domain organization of the members of the BET pro
(B) Structure and binding affinity of Olinone and its analogs for the BRD4-BrD1
experiments, and the error is the SD.
(C) ITC determination of binding affinity of Olinone to the two individual BrDs of B
(D) Selectivity binding of Olinone to BRD4-BrD1 versus BRD4-BrD2, as illustrated
presence of Olinone (red), as well as by ITC.
(E) Phylogenetic tree of the human BrD family. Dots indicate the BrDs for which O
are color coded for high affinity (red), modest affinity (blue), or no binding (gray).
(F) Structural basis of selective binding of Olinone to BRD4-BrD1. Upper left: Cr
diagram. The Fo-Fc electron density map was computed after simulated annealin
(contoured to 1.0 s). Upper right: Structural comparison of BRD4-BrD1 and BRD
with His437 in BRD4-BrD2. Lower left and right: Superimposition of crystal struc
bound to the BRD4-BrD1 in the protein/ligand complex, depicted in ribbon diagra
residues at the ligand-binding site in the protein are color coded by atom type, a
See also Figures S1 and S2 and Table S1.
Chemistry & Biology 21,indole synthesis from treatment of phenylhydrazone 1 with
sulfuric acid (70%) at 0C (Rodriguez and Temprano, 1989).
The resultant 2,3,4,5-tetrahydro-1H-pyrido-[4,3-b]indol-1-one 2
was N-alkylated with a corresponding phthalimido protected
alkyl bromide in the presence of lithium bis(trimethylsilyl) amide
as a base (Coldham et al., 2007). Finally, treatment of N-phthali-
mido protected substituted pyrido-indoles with hydrazine hy-
drate and subsequent acetylation afforded the final compounds
4a to 4d with good yields. Similar procedures were used to
generate compounds 5 and 6 (Figure 1B).
We assessed binding affinity of 4a to 4d, 5, and 6 to BrDs of
BET proteins by using isothermal titration calorimetry (ITC) (Fig-
ure 1C; Figure S2A). The structure-activity relationship data
revealed that the length of the N-alkylated chain plays an impor-
tant role in binding to BRD4-BrD1. An N-alkylated chain of four
methylene units as in 4b seems to be optimal in binding to
BRD4-BrD1, with a binding dissociation constant Kd of 3.4 mM.
This represents a greater than 15-fold improvement in binding
affinity compared with those analogs that comprise three, five,
or six methylene groups (i.e., 4a, 4c, and 4d, respectively) (Fig-
ure 1B). Furthermore, elimination of the acetyl group (5) or the
entire N-acetylated group (6) resulted in a dramatic loss in bind-
ing affinity. We named the best compound of the series 4b Oli-
none for its cellular activity as described below. Consistently,
we observed that Olinone exhibits preferred binding for the
BrD1 over the BrD2 from all three BET proteins BRD4, BRD3,
and BRD2, as assessed by ITC measurements (Figure 1C).
We next profiled Olinone binding selectivity to different BrDs
using 2D 1H-15N heteronuclear single-quantum coherence
(HSQC) NMR spectroscopy (Figure 1D; Figure S2B). The NMR
methodoffers a reliable assessment for ligands that bind to target
proteins with tens to hundredsmicromolar affinity, which is com-
plementary to ITC, which allows quantitative measurements of
ligand binding in low-micromolar affinity. Notably, Olinone
showed modest binding to the BrDs from CBP and PHIP, with
Kd values of 33 and 103.4 mM, respectively; very weak binding
to BRD4-BrD2,with Kd > 300 mM; and almost no detectable bind-
ing to the BrDs frommany other proteins, including BRD7, PCAF,
ASH1L, TAF1L, SMARCA4, BAZ1B, BAZ2B, ATAD2, BPTF, and
TRIM24, which represent different subgroups of the human BrD
family (Figure 1E; Figure S2C). The selectivity for the BrD1 over
the BrD2 of the BET proteins was further confirmed using a fluo-
rescence anisotropy competition binding assay (Figure S2D).the BET BrD1
tein family. ET, extraterminal domain.
, determined by using ITC. Results are representative of three independent
RD4, BRD3, and BRD2.
by 2D 1H-15N HSQC spectra of a given BrD in the free form (black) and in the
linone binding affinity was evaluated in the assay described in (B) and (C). Dots
ystal structure of Olinone (yellow) bound to BRD4-BrD1, depicted in a ribbon
g with the compound omitted from the atomic model and shown in blue mesh
4-BrD2 (PDB accession number 2YEM), showing steric clash between Olinone
tures revealing how Olinone (yellow) and an H4K5ac/K8ac peptide (green) are
m or electrostatic surface representation (right). Side chains of key amino acid
nd bound water molecules are shown as red spheres.
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wild-type or acetyl-lysine binding-deficient mutants of the tan-
dem BrDs of BRD4 proteins, we observed that the two BET
BrDs function almost independently of each other, consistent
with a long linker sequence that connects them (Figure S2D).
Collectively, these results demonstrate that Olinone is a highly
selective inhibitor against the first BrD of the BET proteins.
Molecular Basis of Selective Recognition of BRD4 BrD1
by Olinone
The molecular basis of Olinone recognition of the BrD1 of BET
proteins was revealed by our X-ray crystal structure of the
BRD4 BrD1/Olinone complex, determined at 0.94 A˚ resolution
(Table S1). Olinone forms a chairlike conformation in the bound
state (Figure 1F, upper left), its triheterocyclic moiety as the
seat packs against the side chains of Trp81 and Pro82 in the
one-turn helix Z0, and Ile146 in helix C, and interacts with
Asp144 at the opening of the acetyl-lysine binding pocket
formed between the ZA and BC loops. Asp144 is one of a few
residues that are different between BRD4-BrD1 and BrD2 in
the acetyl-lysine binding site; its corresponding residue in BrD2
is His437, which would clash with the indole moiety of Olinone
(Figure 1F, upper right).
This major contribution to the overall ligand binding by Asp144
was confirmed in our detailed structural analysis of the
BRD4-BrD1/Olinone complex. The acetyl chain of Olinone, as
its back, intercalates into a hydrophobic pocket lined with
Val87, Leu92, Leu94, and Tyr139 of the ZA loop. The carbonyl
oxygen of the acetyl group of Olinone forms a hydrogen bond
(2.9 A˚) to the amide nitrogen of the highly conserved Asn140 in
BRD4-BrD1. Notably, the acetyl chain of Olinone adopted an
almost identical conformation and position as that of the acety-
lated-K5 side chain of histone H4K5ac/K8ac peptide when
bound in BRD4-BrD1, whereas the piperidone ring of Olinone
filled the site for K8ac binding in the H4 peptide (Figure 1F, lower
left and right). This explains the optimal length of the acetyl side
chain of Olinone in its chemical series and Olinone’s effective in-
hibition of BRD4-BrD1 binding to the diacetylated H4K5ac/K8ac
peptide. The binding affinity of the latter interaction, which is
important for BRD4 functions in gene transcriptional regulation
(Chiang, 2009; Filippakopoulos et al., 2012), is estimated to be
a Ki of 26 mM. Given that a few ligand-binding residues in
BRD4-BrD1, such as Ile146 and Asp144, are not conserved
outside the BET proteins in the human BrD family proteins (San-
chez and Zhou, 2009), this structure explains how Olinone isFigure 2. Developmental Expression of BET Family Members in Corpus
droglial Cells
(A) Quantitative RT-PCR showing the transcript levels of Brd2, Brd3, and Brd4
expression (n = 3 animals per age group; one-way ANOVA with Bonferroni postt
(B) MTT assay to measure cell viability in primary cultured mOPCs, primary cult
indicated doses (mM). Red lines indicate the dose range matching with the Kd valu
Olinone and MS417 Kd values for the first and second BrDs of BRD4 (n = 3; one
(C) Selective BET-BrD inhibition decreases histone acetylation. Top: experimenta
acetylation. The graph shows the quantification of the average nuclear residue
sections; n = 3) (two-tailed t test, **p < 0.01, ***p < 0.001). Error bars show ±SEM
(D) Effect of selective BET-BrD inhibition during the early differentiation phase of m
24 hr of BrDi treatment (Olinone at 1 mMandMS417 at 0.05 mM). Results were norm
1 (n = 4; one-way ANOVA with Dunnett’s posttest, ***p < 0.001).
See also Figure S3, and Table S2.
Chemistry & Biology 21,selective for the first BrD of the BET proteins over other BrDs
from different transcriptional proteins.
It is important to note that Olinone has superior selectivity
between the two BrDs of BET proteins, even as compared with
the recently developed MS436, a diazobenzene compound
(Zhang et al., 2013), or the BET-specific BrDi MS417, which is
a thienotriazolo-diazepine compound (Zhang et al., 2012b) and
structurally related to (+)-JQ1 (Filippakopoulos et al., 2010) and
I-BET (Nicodeme et al., 2010). These BET-specific BrDis,
particularly MS417 and (+)-JQ1, have high affinity for BrD
(Kd = 20–100 nM) but do not discriminate between the first and
second BrDis of the BET proteins, because of greater than
95% sequence identity at the acetyl-lysine binding pocket.
Selective BET-BrD1 Inhibition Favors, whereas Broad
BET BrD Inhibition Prevents the Differentiation
of Oligodendrocyte Progenitors
To begin evaluating the differential effects of selective inhibitors
of the first BrD (such as Olinone) and compare them with those
of broad BET inhibitors (i.e., MS417 and JQ1), we measured
the levels of expression of the BET protein-encoding genes in
the developing white matter tracts of the mouse brain. Of the
analyzedmolecules,Brd2was themost abundant BET transcript
in the neonatal brain (Figure 2A). However, it is worth noting that
the levels of all the BETs (i.e., Brd3, Brd4 long isoform, and Brd4
short isoform) progressively declined in developing white matter
tracts during a temporal window that was coincident with the
differentiation of progenitors into myelin-forming oligodendro-
cytes, as detected by the expression of the myelin gene Mbp
(Figure 2A).
To assess the ability of Olinone to modulate oligodendrocyte
progenitor differentiation in mouse cultures, we first determined
the effect of Olinone and MS417 on cell viability after 72 hr
of treatment with increasing concentrations of BrDi, using a
1-methyl-1 H-tetrazole-5-thiol (MTT) assay (Figure 2B). No sig-
nificant cytotoxicity was observed for Olinone or its inactive
analog compound 5, up to a concentration of 10 mM. In contrast,
treatment with MS417 was toxic at doses of 500 nM and above
(Figure 2B). Therefore, we opted to use Olinone at 1 mM and
MS417 at 0.05 mM for most of the cellular studies.
We had previously reported that global histone acetylation
characterizes proliferating progenitors and that deacetylation is
necessary to initiate a differentiation program (Marin-Husstege
et al., 2002; Shen et al., 2005). We therefore asked whether
treatment with the BrD1 specific inhibitor Olinone or with theCallosum and Characterization of BrD Inhibition Effect in Oligoden-
-long and Brd4-short isoforms in developing corpus callosum relative to 18S
est, ***p < 0.01 versus P0).
ured mouse astrocytes, and Olineu cells after 72 hr of treatment with BrDi at
es of the inhibitors, showing no toxicity at the indicated concentrations. Right:
-way ANOVA with Dunnett’s posttest, *p < 0.05, ***p < 0.001).
l timeline. Bottom: automated high-throughput confocal screening for histone
-specific histone acetylation staining intensity in reference to DMSO (n = 20
.
OPCs. qRT-PCR showing the expression levels of differentiation markers after
alized to Gapdhwith relative mRNA levels in DMSO-treated control cells set to
841–854, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 845
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lation and gene transcription in immortalized oligodendrocyte
progenitors (Olineu). The first experiment was conducted in the
presence of mitogens, which represent a strong stimulus toward
the persistence of global acetylation in these cells (Wu et al.,
2012). Interestingly, in these cells, Olinone treatment resulted
in an average reduction of histone H3 global acetylation, de-
tected primarily at residues H3K14ac and H3K36ac, with little
changes at H4K5ac and H4K12ac (Figure 2C). Treatment with
MS417, in contrast, was less effective at reducing the histone
acetylation levels at H3K14, although it decreased the levels of
H3K36ac (Figure 2C). Despite the similar effect on histone de-
acetylation and on the expression of oligodendrocyte specific
genes (Figure 2D), treatment of cells with Olinone consistently
increased the transcript levels of myelin genes associated with
the differentiated phenotype, whereas treatment with MS417
decreased the levels of these genes while increasing transcripts
characteristic of the progenitor stage (Figure 2D). These results
suggested that BrD1-specific inhibition promoted differentiation,
whereas inhibition of both BrD1 and BrD2 prevented it and re-
tained the cells at a progenitor stage.
Because an obligatory relationship exists between cell-cycle
exit and differentiation in oligodendrocyte lineage cells (Swiss
and Casaccia, 2010), and BrDis have been reported to inhibit
proliferation of cancer cells, we asked whether the differential
effect on differentiation observed after treatment with Olinone
or MS417 could be due to a distinct modulation of the cell
cycle. To address this question, we adopted three different ap-
proaches: immunohistochemistry with antibodies for the cell-cy-
cle marker Ki67 (Figure 3A), expression levels of cell-cycle genes
(Figure 3B), and fluorescence-activated cell sorting (FACS) anal-
ysis (Figure 3C). A detailed quantification of Olinone- or MS417-
treated cells using immunoreactivity for Ki67 in order to identify
proliferating cells did not reveal any difference among treatment
groups (Figure 3A). Gene expression data analysis revealed an
overall interesting effect of MS417, but not Olinone, on the tran-
script levels of cell-cycle genes (Figure 3B). Consistent with
the inhibitory effect of MS 417, treatment with this broad BET in-
hibitor decreased the expression of the gene encoding for
p21Waf1, which had been previously shown to positively affect
oligodendrocyte differentiation (Zezula et al., 2001) while
increasing the levels of cell-cycle genes preventing differentia-
tion, such as E2F1 (Magri et al., 2014b) and c-Myc (Magri
et al., 2014a). Finally, a measure of the DNA content by FACS
analysis did not reveal significant differences in the relative pro-
portion of cells in the different stages of the cell cycle (Figure 3C).
Taken together, these data suggest that the prodifferentiation
effect of the BrD1 inhibitor Olinone could not be interpreted as
the consequence of precocious cell-cycle exit.
Temporal Control of BrDi Effectiveness on
Oligodendrocyte Progenitor Differentiation
To gain a better understanding of the effect of the BrD1-specific
or broad BET BrDis on differentiation, we conducted a dose-
response experiment and measured the transcript levels of
late differentiation genes. In both cases, we detected a dose-
dependent response, corresponding to either MS417-mediated
decrease or Olinone-induced increase ofmyelin gene transcripts
at a dose comparable with the in vitro binding affinity to the846 Chemistry & Biology 21, 841–854, July 17, 2014 ª2014 Elsevier Lindividual BrDs of BET proteins. This effect was clearly detect-
able as early as the first 24 hr of differentiation (Figure S3).
To further determine the window of effectiveness of BrDi treat-
ment, we treated cells with either Olinone or MS417 for different
amount of time in the presence of mitogens or in their absence. A
24 hr treatment in the presence of mitogens was not sufficient to
detect the effects of MS417 or Olinone (Figure 4A). In contrast,
treatment for 72 hr starting after the removal of mitogens was
sufficient to alter the expression of the late differentiation genes
(Figure 4B). Thus, inhibition of BrD binding was not sufficient to
remove the inhibitory block of differentiation caused by mitogen
stimulation and was detected only after the cells exited the cell
cycle. The first 24 hr following cell-cycle exit represents an
important critical window for the onset of a complex transcrip-
tional program of differentiation. We therefore asked whether
BrD inhibition during this critical period was sufficient to induce
long-lasting changes. For this reason, after the first 24 hr of treat-
ment, we washed out the drugs and allowed the cells to recover
in differentiation medium (DM) prior to measuring the transcript
levels of differentiation genes (Figure 4B). In these conditions,
the levels of gene transcripts measured after washout did not
reveal any change, which indicated that the effect of blocking
BrDs was not stable but reversible over time.
The next question was to define whether inhibition of one or
both BrDis would also be detected if cells were treated after
the program of oligodendrocyte differentiation had started
(i.e., after at least 48 hr in mitogen-free DM) (Figure 4C). In this
case, the broad BET inhibition by MS417 still significantly
decreased the expression of late differentiation genes, though
to a lesser extent than continuous treatment, while the prodiffer-
entiation effect of blocking only the first BrD1 by Olinone was
dramatically reduced, with the exception of Mog levels (Fig-
ure 4C). Collectively, these data suggest that BET activity in
oligodendrocyte lineage cells is differentially affected by inhibi-
tors of the first BrD1 or of both BrDs of BET proteins.
Specificity and Off-Target Effects
We then examined the specificity of the effect of BrDi on oligo-
dendrocyte differentiation by treating progenitors with structur-
ally related but inactive compounds and conducted a detailed
immunophenotypic (Figure 5A) and transcriptional (Figure 5B)
characterization of mouse primary oligodendrocyte progenitor
differentiation. Immunoreactivity for the proteoglycan NG2
was used to identify early progenitors, O4 to label cells express-
ing lipid sulfatides at an intermediate stage of maturation, and
myelin basic protein (MBP) to identify differentiated oligodendro-
cytes. In untreated cultures, the progression of progenitors to
mature oligodendrocytes was characterized by the progressive
decrease of NG2 and the gradual acquisition of O4 immunoreac-
tivity, followed by the acquisition of a myelinating phenotype,
characterized by the extension ofmyelin membranes recognized
by both O4 and MBP antibodies.
Treatment of primary oligodendrocyte progenitors with the
BrD1-specific inhibitor Olinone promoted a shift toward the
differentiated phenotype, as documented by the increased per-
centage of O4+ cells (Figure 5B), compared with DMSO-treated
cells. This effect was not detected in cells that were treated with
the inactive Olinone analog compound 5. Treatment of primary
oligodendrocyte progenitors in the exact same conditions withtd All rights reserved
Figure 3. Treatment with BrDi Does Not Affect the Proliferation of Primary Cultured mOPCs and Cell-Cycle Exit upon Differentiation Stimuli
(A) Representative confocal images of proliferating mOPCs stained with Ki67 antibody (green) and DAPI (blue). The scale bar represents 50 mm. The graph rep-
resents the percentage ofmean pixel intensity. Results shown are relative DMSO-treated control cells (set to 100%) (n = 3; one-way ANOVAwithDunnett’s posttest).
(B) qRT-PCR showing the expression levels of cell-cycle genes after 24 hr of BrDi (Olinone at 1 mM and MS417 at 0.05 mM). Results were normalized to Gapdh,
with relative mRNA levels in DMSO-treated control cells set to 1 (n = 3; one-way ANOVA with Dunnett’s posttest, ***p < 0.001). Error bars show ±SEM.
(C) Cell-cycle analysis of BrDi-treated mOPCs for 24 hr as indicated. Color bars represent percentage of cells in each cell-cycle phase (n = 2; two-tailed t test).
Error bars show ±SEM.
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tently opposite effects to those induced by Olinone. MS417
antagonized the progression toward a mature phenotype and
reduced the number of NG2+/O4+ cells (Figure 5B). The effect
was highly specific as the inactive enantiomer of MS417 (Zhang
et al., 2012a), called MS566, was incapable of eliciting the same
biological effect (Figure 5B). At a transcriptional level, the prodif-
ferentiation effect of Olinone, but not compound 5, was also
detected by the increased transcript levels for the late-differen-
tiation markers Mag, Mog, Plp, and Mbp (Figure 5C), whereas
MS417 treatment decreased the expression of these late-differ-Chemistry & Biology 21,entiation markers in a dose-dependent fashion while increasing
the expression of the transcriptional inhibitor of myelin genes,
Hes5 (Figure 5C).
Selective Inhibition of the BrD1 Enhances, whereas
Inhibition of Both BET BrDs Prevents the Differentiation
of Oligodendrocyte Progenitors
To begin to understand whether the inhibitory effect of MS 417
was consequent to the inhibition of both BrDs of BET proteins,
we used two distinct approaches. First, we asked whether
Brd2 in cultured progenitors was also the most prominent BET841–854, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 847
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Figure 5. Olinone Specifically Promotes the
Expression of theOligodendrocyte Interme-
diate Differentiation Marker O4
(A) Top: experimental timeline. Bottom: confocal
image of mOPCs treated for 24 hr with DMSO,
Olinone (1 mM), compound 5 (1 mM), MS417
(0.05 mM), andMS566 (0.05 mM) in DM and stained
with NG2 (green), O4 (red) antibodies, and DAPI
(blue). The scale bar represents 50 mm.
(B) Graph showing the quantification of the per-
centage of NG2+/O4+ staining in treated cells
relative to DMSO (n = 5–7 sections per condition,
n = 3 independent experiments; one-way ANOVA
with Dunnett’s post test, **p < 0.01).
(C) qRT-PCR showing the expression levels of
differentiation markers after 24 hr of BrDi (Olinone
at 1 mM, compound 5 at 1 mM, MS417 at 0.05 mM,
MS566 at 0.05 mM). Results were normalized to
Gapdh, with relative mRNA levels in DMSO-
treated control cells set to 1 (n = 4; one-way
ANOVA with Dunnett’s posttest, ***p < 0.001).
Chemistry & Biology
Selective BrD Modulation in Gene Transcriptionprotein to be detected in the oligodendrocyte lineage cells (Fig-
ure 6A), which was consistent with our in vivo studies in devel-
oping myelinating tracts (Figure 2A). We then expressed either
a wild-type EGFP-tagged Brd2 (EGFP-Brd2wt) molecule or a
mutant form of Brd2 (EGFP-Brd2mut) lacking the acetyl-lysine
binding domains in the first and second BrD of the protein mole-
cule (Hnilicova´ et al., 2013) in Olineu cells and asked whether
the twomolecules were differentially distributed within the nuclei
of transfected cells. Although the EGFP-Brd2wt transfected
cells were characterized by a nuclear diffuse distribution, those
transfected with the mutant eGFP-Brd2mut, lacking the ability
to bind acetyl-lysine, showed a very distinctive punctate
distribution (Figure 6B). Treatment with the BrD1-specific inhib-
itor Olinone did not alter the distribution of eGFP-Brd2wt,Figure 4. Temporal Control of BrD Inhibition on OPC Differentiation
(A) BrDis do not have broad effects on the expression of oligodendrocytic lineage markers in proliferating con
PCR showing the expression levels of differentiation markers after 24 hr of BrDi treatment (Olinone at 1 mM an
Results were normalized to 18S with relative mRNA levels in DMSO-treated control cells set to 1 (n = 4; one-
(B) Top: different experimental paradigms of BrDi treatment during mOPC differentiation. Bottom: qRT-PC
ferentiation markers (Mag,Mog,Mbp, and Plp) in mOPCs differentiated for 72 hr and treated with BrDi as ind
differentiation and then kept in DM with no BrDi. Doses used were 1 mMOlinone and 0.05 mMMS417 (n = 3; o
**p < 0.01, ***p < 0.001).
(C) Top: different experimental paradigms of BrDi treatment. Bottom: qRT-PCR results showing the transcri
Mbp, and Plp) in mOPCs differentiated for 72 hr and treated with BrDi as indicated: (I) during 72 hr or (III) durin
1 mM Olinone and 0.05 mM MS417 (n = 3; one-way ANOVA with Dunnett’s post test, *p < 0.05, **p < 0.01, **
Chemistry & Biology 21, 841–854, July 17, 2014whereas treatment of MS417 induced a
punctate distribution of the fusion pro-
tein, which resembled that observed
in eGFP-Brd2mut-transfected cells (Fig-
ure 6B). Taken together, these data sug-
gest that the second BrD of Brd2 is
important for its subcellular localization,
given that Olinone, which inhibits only
the first BrD, did not have any effect on
eGFP-Brd2wt, whereas MS417 (inhibit-
ing both the first and second BrDs of
Brd2) as well as a mutant Brd2 in both
BrDs showed altered nuclear distribution.The second approach entailed the use of additional chemical
probes selective for the inhibition of only the first (MS611) or only
of the second (MS765) BrD of BET proteins (Figure S2D; see also
the chemical synthesis in the Supplemental Information and Fig-
ure S4). Notably, MS765, which is also known as RVX-208, is a
compound that was developed by Resverlogix and has been
shown to have 15- to 30-fold selectivity for the second BrDs
over the first of BET proteins (McLure et al., 2013; Picaud
et al., 2013). To investigate whether inhibitors of only the first
or second BrD of BET modulated the progression of oligoden-
drocyte progenitors toward a differentiated phenotype, we char-
acterized the effect of 72 hr treatment with Olinone and MS611
(as inhibitors of the first BrD), MS765/RVX-208 (as an inhibitor
of the second BrD), and MS417 (as an inhibitor of both BrDs).ditions. Top: experimental time line. Bottom: qRT-
d MS417 at 0.05 mM) in the presence of mitogens.
way ANOVA with Dunnett’s posttest, ***p < 0.001).
R results showing the transcript levels of late dif-
icated: (I) during 72 hr or (II) during the first 24 hr of
ne-way ANOVA with Dunnett’s posttest, *p < 0.05,
pt levels of late differentiation markers (Mag, Mog,
g the last 36 hr of differentiation. Doses used were
*p < 0.001). Error bars show ±SEM.
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Figure 6. Selective BrDi Inhibition Differentially Affects Brd2 Nuclear Localization and the Progression of Primary OPCs toward a Fully
Differentiated Phenotype
(A) qRT-PCR showing the relative expression levels of Brd2, Brd3, and the long and short isoforms of Brd4 in primary cultured mOPCs. Brd2 is the highly ex-
pressed isoform in mOPCs. Olig2 (as a marker of oligodendrocyte lineage), Mbp (as a marker of differentiated oligodendrocytes), and Gfap (as a marker of
astrocytes) levels were also determined as controls. Results were normalized to 18S (n = 3). Error bars show ±SEM.
(B) Changes in Brd2 nuclear localization after BrDi treatment ± trichostatin A (TSA). Olineu cells were transfected with Brd2-eGFP or mutBrd2-eGFP (with two
BrDs mutated) in the presence or absence of BrDi (Olinone 1 mM,MS417 0.05 mM); DMSO is used as control. TSA (30 mM) was added after 24 hr of BrDi treatment
(legend continued on next page)
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Selective BrD Modulation in Gene TranscriptionDifferentiation of progenitors into oligodendrocyte was moni-
tored by measuring transcripts for late differentiation genes
(Mag, Mog, Plp, and Mbp), assessing immunoreactivity for late
differentiation markers (MBP+/O4+) and quantifying the number
of membrane-bearing cells. We observed that treatment of Oli-
none and with the other inhibitor of the first BrD, MS611,
increased expression of late differentiation markers (Figure 6C),
whereas the inhibitor of the second BrD, MS765/RVX-208, had
no effect, and the broadMS417 inhibitor inhibited the expression
of these genes (Figure 6C). The number of MBP+ membrane-
bearing cells (Figure 6D; Figure S5) was similarly increased
by Olinone or MS611, unchanged by MS765/RVX-208, and
decreased by MS417 treatment (Figure 6E).
Collectively, our results suggest that selective inhibition of the
first BrD (such as by Olinone or MS611) facilitates the progres-
sion of primary oligodendrocyte progenitors toward a differenti-
ated phenotype, inhibition of the secondBrD (such as byMS765/
RVX-208) has no effect, and inhibition of both BrDs of BET
proteins (such as MS417) negatively affects the differentiation
process.
Because of the dynamic nature of lysine acetylation, chemi-
cal inhibition of these BrDs may result in lysine deacetylation
and subsequent ubiquitination-mediated degradation of the
BrD-binding partners. Therefore, chemical inhibition of the
two different BrDs is likely to yield distinct functional outcomes.
In this study, we compared the effect of a selective inhibitor
(Olinone) for the first BrD of BET proteins with that of an inhib-
itor (MS417) that is equally effective for both BrDs and
observed dramatic differences in the biological response of
oligodendrocyte progenitors to these treatments. Whereas Oli-
none promoted differentiation, MS417 inhibited it. This effect
was associated with the upregulation of genes such as E2f1
and Myc, which we have shown to be inhibitory for differentia-
tion (Magri et al., 2014a, 2014b) and the downregulation of pro-
differentiation genes such as Cdkn1b (Zezula et al., 2001). One
explanation is that under MS417 treatment, a key transcription
factor that is recruited by BET proteins could be degraded in
cells, whereas Olinone treatment would leave such a transcrip-
tion factor intact because of its association with the second BrD
of BET proteins. Given the complex nature of gene transcription
progression of oligodendrocyte progenitor differentiation, the
identification of such a transcription factor(s), and the detailed
mechanism of action of chemical inhibition of BET proteins by
Olinone and/or MS417 will have to await future investigation.
Finally, recent studies show that some kinase inhibitors,
such as BI-2536 and TG-101348, developed against PLK1
and JAK2-FLT3 kinases, respectively, have off-target effectsin order to reduce rapid histone acetylation. Cells were fixed at the indicated time
represents 50 mm. Error bars show ±SEM.
(C) Top: experimental timeline. Transcript levels of late differentiationmarkers (Ma
in response to 72 hr of BrDi treatment (Olinone at 1 mM, compound 5 at 1 mM, M
Results were normalized to Gapdh with relative mRNA level in DMSO-treated co
**p < 0.01, ***p < 0.001). Error bars show ±SEM.
(D) Representative confocal images of mOPCs treated with DMSO, Olinone (1 mM)
and DAPI (blue). The scale bar represents 100 mm.
(E) Graph showing the quantification of the percentage of mature MBP+membran
way ANOVA with Dunnett’s post test, *p < 0.05).
See also Figures S4 and S5.
Chemistry & Biology 21,on BrDs in gene activation, including BET BrDs (Ciceri et al.,
2014; Ember et al., 2014). Although the reverse may also be
possible, this is less likely for Olinone because of its distinct
chemical structure from those dual kinase-bromodomain inhib-
itors. Moreover, similar results obtained with MS611, which
shares the same selectivity for the first BrD over the second
BrD of BET proteins as that of Olinone, further supports the
findings of this study.
SIGNIFICANCE
BET family proteins, through their BrD/acetyl-lysine binding
capability, regulate gene transcription in chromatin in multi-
ple steps, including the recruitment of transcription factors
to target genes, assembly of the mediator complex at
enhancer sites, and activation of paused RNA polymerase
II machinery complexes for productive transcriptional elon-
gation (Chiang, 2009). The two BrDs of BET proteins, as
shown in BRD3 and BRD4, have context dependent different
functions in regulation of ordered gene transcription (Gams-
jaeger et al., 2011; Huang et al., 2009; Jang et al., 2005;
Lamonica et al., 2011; Schro¨der et al., 2012; Shi et al., 2014;
Yang et al., 2005; Zhang et al., 2012a).
In this study, we highlight the functional importance of
chemical modulation of acetylation-mediated protein-pro-
tein interactions in transcriptional control of OPC differen-
tiation. We identify Brd2 as the prominent BET expressed
in the oligodendrocyte lineage cells. In contrast to what
has been reported for other cell types, treatment of oligo-
dendrocyte progenitors with BrDis did not modulate the
acetylation of histone H4 and did not affect proliferation.
These cells were quite responsive to treatment with selec-
tive chemical probes specific for the first, second, or both
BrDs of BET proteins. In this functional context, we demon-
strate that a small-molecule BrDi, designed to selectively
modulate the master chromatin regulators BET proteins,
could positively or negatively influence the differentiation
of oligodendrocyte progenitors, depending on the targeted
BrD. Our data further indicate that a complete chemical inhi-
bition of BET BrD/acetyl-lysine binding activity may possess
adverse effects on oligodendrocyte progenitor differentia-
tion, an important step for myelination of axons. Overall,
this study opens opportunities for the future development
of new therapeutic treatments of demyelinating disorders
and also novel chemical agents that could improve the effi-
ciency of the lineage progression of adult stem cells into
specialized cell types.points (1 hr of TSA treatment and 6 hr of TSA treatment) (n = 3). The scale bar
g,Mog,Mbp, Plp, and Sirt2) and themyelin gene transcriptional inhibitor (Hes5)
S417 at 0.05 mM, MS566 at 0.05 mM, MS611 and MS765/RVX-208 at 0.5 mM).
ntrol cells set to 1 (n = 8; one-way ANOVA with Dunnett’s posttest, *p < 0.05,
, andMS417 (0.05 mM) during 72 hr in DMand stained withMBP antibody (gray)
e-bearing cells relative to DMSO (n = 3 with 7 or 8 sections per condition; one-
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ITC
Experiments were carried out on a GE MicroCal auto-ITC200 instrument at
15C while stirring at 1,000 rpm in the ITC buffer at pH 7.4, consisting of
50 mM sodium phosphate and 150 mM sodium chloride, as described previ-
ously (Zhang et al., 2012a). Compound concentration was determined by
NMR and protein concentrations by A280 measurements. The protein sample
(75 mM) was placed in the cell, whereas the microsyringe (130 ml) was loaded
with a solution of the correspondent compound (0.8 mM) in the ITC buffer. All
titrations were conducted using 20 identical injections of 2 ml, with a duration
of 4 s per injection and a spacing of 150 s between injections. The heat of
dilution was determined by independent titrations (protein into buffer) and
was subtracted from the experimental data. The collected data were impli-
cated in the MicroCal Origin software supplied with the instrument to yield
enthalpies of binding (DH) and binding constants (KB). Thermodynamic
parameters were calculated (DG = DH  TDS = RTlnKB, where DG, DH,
and DS are the changes in free energy, enthalpy, and entropy of binding,
respectively). In all cases, a single binding site model was used.
Protein Crystallization, X-Ray Diffraction Data Collection,
and Structure Determination
Purified BRD4-BrD1 protein (14 mg/ml) was mixed with Olinone 4b at a 1:10
molar ratio of protein to ligand. The complex was crystallized using the sitting
drop vapor diffusion method at 20C by mixing 1 ml of protein solution with 1 ml
of the reservoir solution, which contains 25% tert-Butanol and 0.1 M Tris-HCl
(pH 8.5). Crystals were soaked in the corresponding mother liquor supple-
mented with 20% ethylene glycerol as a cryoprotectant before freezing in
liquid nitrogen. X-ray diffraction data were collected at 100 K at beamline
X6A of the National Synchrotron Light Source (NSLS) at Brookhaven National
Laboratory. Data were processed using the HKL-2000 suite (Otwinowski and
Minor, 1997). The BRD4-BRD1 structure was solved by molecular replace-
ment using the programMOLREP (Vagin and Teplyakov, 1997), and the struc-
ture refinement was done using the program Refmac (Murshudov et al., 1997).
The graphics program COOT (Emsley and Cowtan, 2004) was used for model
building and visualization. Crystal diffraction data and refinement statistics
for the structure are displayed in Table S1 (see Supplemental Information).
Primary Oligodendrocytes
OPCs were prepared by sequential immunopanning and kept under undiffer-
entiating conditions, as described previously (Watkins et al., 2008), until the
onset of experiments. Briefly, OPCs were isolated from one P6 mouse pup
brain using an immunopanning system enabling purity of 95%. The dissected
cortex was chopped in papain buffer, incubated for 20 min at 37C, and
titrated in ovomucoid solution (CellSystems). The single-cell solution was
centrifuged at 1,000 rpm for 10 min and resuspended in panning buffer and
transferred to a bacterial culture plate coated with Anti-BSL1 Griffonia simpli-
ficonia lectin (Vector Labs, L-1100), for negative selection for 15 min, followed
by a positive selection stepwith rat antimouse CD140a (Research Diagnostics,
10R-CD140AMS) as a primary antibody and AffiniPure goat antirat immuno-
globulin G (H+L) (Dianova, 112-005-003) as a secondary antibody for 45 min.
The supernatant was aspirated, and the positive selection plate was washed
with Dulbecco’s PBS (DPBS). The adherent OPCswere removed using trypsin,
centrifuged for 10 min at 1,000 rpm, resuspended in mouse OPC (mOPC) Sato
(Watkins et al., 2008), and plated in a T75 culture flask coated with polylysine.
The OPCs were cultured in a humidified incubator at 5% CO2 and 37
C, with
media changes every 2 days. OPC were maintained proliferating in the pres-
ence of basic fibroblast growth factor (bFGF) (20 ng/ml) and platelet-derived
growth factor (PDGF) (10 ng/ml), while oligodendrocyte differentiation was
induced by culturing the cells in the absence of mitogens and adding T3
60 nM (Sigma, T5516) to Sato medium.
Olineu Transient Transfection
Olineu cells (15,000 cells/well) were grown on CC2-coated eight-well cham-
bers (Lab-Tek) for all transfection experiments. These cells were transiently
transfected using X-tremeGENE 9 DNA transfection reagent (Roche Diagnos-
tics) following the manufacturer’s protocol and using equal amounts of the
eukaryotic expression vectors pEGFP-C1-Brd2 and pEGFP-C1-Brd2mut852 Chemistry & Biology 21, 841–854, July 17, 2014 ª2014 Elsevier L(with both BrDs mutated), previously described by Hnilicova´ et al. (2013). After
24 hr of transfection, cells were treated for 24 hr with either BrDis (Olinone,
MS417) at indicted concentrations or with DMSO as negative control. At this
time point, cells were fixed and stained with DAPI (1:10000; Molecular Probes)
for immunochemistry.
Proliferation Assays
Mouse primarily cultured oligodendrocytes were cultured in CC2-coated
eight-well chambers (Lab-Tek) in Sato medium with growth factors (bFGF
and PDGFaa). Cells were treated with either BrDis at indicated concentrations
or DMSO as control for 24 hr. To determine changes in proliferation, cells
were fixed and immunolabeled with antibodies against the cell proliferation
marker Ki67 (ab14298, 1:1000) for 1 hr at room temperature (RT).
Immunohistochemistry
Immunohistochemistry of cultured cells with O4 antibodies was performed
live. Cells were grown on CC2-coated eight-well chambers (Lab-Tek) for all
immunocytochemistry. For staining oligodendrocyte lineage markers, cells
were rinsed gently with PBS and incubated live with O4 hybridoma superna-
tant (1:10, gift from Dr. Bansak, University of Connecticut) for 30 min at
37C. Cells were then fixed with 4% paraformaldehyde (PFA) for 15 min at
RT and first incubated with blocking/permeabilization solution (phosphate
buffer with gelatin bovine albumin [0.1 M phosphate buffer, 0.1% gelatin,
1% BSA, azide] PGBA plus 10% normal goat serum and 0.5% Triton X-100)
for 1 hr at RT. For costaining experiments, cells were incubated with additional
primary antibodies against NG2 (Chemicon AB5320, 1:300) and MBP (Cova-
nce SMI99, 1:500) overnight at 4C. A 1 hr incubation with secondary fluores-
cent antibodies (Alexa Fluor 488 or 546) was performed the following day with
counterstaining for DAPI (1:10000; Molecular Probes) to visualize cell nuclei.
Image Acquisition and Quantification
Images were captured at 203 and oil immersion 633 objective using LSM 710
Metaconfocal laser scanning microscope (Carl Zeiss MicroImaging). For the
quantification of the cells at different stages, three fields of each well and
four wells of each condition were analyzed, and the immunopositive cells
were counted using ImageJ software (NIH). To characterize the 24 hr culture,
the proportion of NG2;O4 double positive was calculated by referring to the
total number of cells (DAPI+). To characterize the 72 hr culture, the percentage
of MBP+ membrane-bearing cells was calculated by dividing the number of
each type of cells by the number of total number of cells (DAPI+). OPC prolif-
eration was determined by measuring the mean pixel intensity of DAPI/Ki67+
cells (>99% in each group) relative to DMSO values. One-way ANOVA with
Dunnett’s multiple-comparison test was performed to assess statistical differ-
ences between control and experimental conditions after combing the total
number of cells in each group, with a significance threshold of p < 0.05.
Acetyl Histone Detection
Olineu cells were plated on 0.1 mg/ml poly-d-lysine (Sigma P7886) coated
96-well plates at a density of 5,000 cells/well. Oligodendrocyte differentiation
medium was supplemented with 1% horse serum (Invitrogen 16050). Twenty-
four hours after plating, cells were treated with either Olinone at 1 mM or
MS417 at 0.05 mM, as well as DMSO as a control for 48 hr. Cells were gently
washed with PBS after completion of the treatment and fixed with 4% PFA for
20 min at RT. Cells were then washed and permeabilized with 0.1% triton
for 30 min at RT followed by incubation in PGBA plus 10% normal goat serum
for 1 hr. Cells were incubatedwith primary antibodies (H3-Acteyl 1:500Upstate
06-599; H3AcK14 1:500 Active Motif 39599; H3AcK36 1:1000 Active Motif
39380; H4AcK5 1:2000 Active Motif 39584 and H4AcK12 1:1000 Active Motif
39928) overnight at 4C. The following day, samples were incubated for 1 hr
with secondary fluorescent antibody Alexa Fluor 488 (Invitrogen A11034)
and counterstained for DAPI (1:10,000, Molecular Probes). Measurement of
the pixel intensity of each primary antibody listed above was accomplished
by automated high-throughput screening using plate readers (Perkin Elmer
EnVision; TECAN Sapphire and Genios) and high-content microscopes
(Molecular Devices ImageXpress Ultra) at the Integrated Screening Core
Facility at the Icahn School of Medicine at Mount Sinai. Two-tailed Student’s
t tests were performed to assess statistical differences between the average
values in each condition, with a significance threshold of p < 0.05.td All rights reserved
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mOPCs were grown in proliferating conditions until they reached 75% of
confluence. At this point, differentiation was induced, and the cells were
treated with BrDi as indicated. After 24 to 30 hr of treatment, cells were rinsed
twice with DPBS, trypsinized, and pelleted with PBS. One million cells per
condition were fixed with cold 70% ethanol overnight. Cell-cycle analysis
was performed using the Muse Cell Cycle Analyzer (Millipore, MCH100106)
following the manufacturer’s protocol.
Statistical Analysis
Unless otherwise stated, all experiments were performed a minimum of three
times. The results represent the mean ± SEM. We compared the data using
one-way ANOVA or two-tailed t tests as appropriate and defined statistical
significance at p < 0.05.
ACCESSION NUMBERS
Structure factors and coordinates for the BRD4 BrD 1 in complex with Olinone
are deposited at the Research Collaboratory for Structural Bioinformatics
(RCSB) Protein Data Bank under RCSB accession number rcsb085830 and
Protein Data Bank (PDB) accession number 4QB3.
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